About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Glenmark and GBR401

by Savitha C Muppala on April 1, 2011 at 8:30 PM
Font : A-A+

 Glenmark and GBR401

The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India.

The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Color Blindness Calculator Vent Forte (Theophylline) Calculate Ideal Weight for Infants How to Reduce School Bag Weight - Simple Tips Selfie Addiction Calculator Iron Intake Calculator Drug Side Effects Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Diaphragmatic Hernia
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Glenmark and GBR401 Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests